Therefore, we replace the two viral γ34.5 neurovirulence genes with the human MSLN gene under the control of a CMV promoter to allow for the delivery of MSLN to the pancreatic cancer cell surfaces (Fig. 1a) [29]. This evidence concerns the gene MSLN and pancreatic neoplasm.